Menopa’s subsidiary, Lurasidone Hydrochloride API, received approval
August 5, 2025
Source: drugdu
53
On August 4, Mino Pharma(603538) announced that its subsidiary Anhui Minova Pharmaceutical Chemical Co., Ltd.'s lurasidone hydrochloride API has passed the CDE technical review of the National Medical Products Administration and obtained the " Chemical Raw Materials"The drug's registration number is Y20230000666, and its indication is the treatment of schizophrenia.
The R&D investment totaled 1.35 million yuan (unaudited). The approval of the lurasidone hydrochloride API confirms that the product meets the relevant national drug registration requirements and is eligible for sale in the domestic market. This will further enrich the company's product line, expand its business scope, and enhance its advantages in the integrated production of APIs and preparations. According to the IMS database, global sales of preparations for this product are expected to reach approximately US$309 million in 2024, with API sales reaching 13,457.74 kilograms.
In the first quarter of 2025, Minopharm achieved revenue of 276 million yuan and net profit attributable to shareholders of the parent company of 21.22 million yuan.
https://finance.eastmoney.com/a/202508043475281372.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- After the impact of centralized procurement, this old pharmaceutical company gambled heavily on research and development August 20, 2025
- Zhifei Biological has turned from profit to loss, and the transformation and breakthrough of domestic vaccines have become a trend August 20, 2025
- The subsequent R&D nodes and external licensing expectations of the innovative vaccine pipeline are worth paying attention to August 20, 2025
- Zhifei Bio’s subsidiary’s vaccine application for clinical trial accepted August 20, 2025
- Seven blood metabolites associated with excessive daytime sleepiness August 20, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
